by Madaline Spencer | Aug 1, 2025
The U.S. Food and Drug Administration (FDA) has approved Skytrofa (lonapegsomatropin-tcgd; TransCon hGH) for the replacement of endogenous growth hormone in adults with growth hormone deficiency (GHD). It was approved for the treatment of pediatric GHD by the FDA in...
by Madaline Spencer | Aug 1, 2025
Henry Wong, MD, PhD, Dermatologist at the San Diego Veterans Hospital and the University of California San Diego (UCSD), discusses cutaneous T-cell lymphoma (CTCL). CTCL is a rare group of malignancies that attack the body’s immune lymphatic system, affecting...
by Madaline Spencer | Jul 31, 2025
The U.S. Food and Drug Administration (FDA) has approved Doptelet (avatrombopag) for the treatment of persistent or chronic immune thrombocytopenia (ITP) in patients one year and older who have had insufficient response to prior therapy. ITP is a rare bleeding...
by Madaline Spencer | Jul 30, 2025
Paula Rodríguez-Ortero, MD, PhD, Hematologist at the University of Navarra, discusses results of PD-1 inhibitor combination therapy in patients with multiple myeloma (MM). MM is a bone marrow-based plasma cell neoplasm characterized by a serum monoclonal...
by Madaline Spencer | Jul 28, 2025
Laura Adang, MD, PhD, Assistant Professor at Perelman School of Medicine at University of Pennsylvania, discusses a cohort study conducted analyzing pre-diagnostic symptoms and time-to-diagnosis in patients with metachromatic leukodystrophy (MLD). MLD is...
